Oncotype DX (Genomic Health, Redwood City, CA, USA, current list price $4,350.00) is a multigene quantitative reverse transcription-polymerase chain reaction-based assay that estimates the risk of distant recurrence and predicts chemotherapy benefit for patients with estrogen receptor (ER)-positive breast cancers. Studies have suggested that standard histologic variables can provide similar information. Klein and Dabbs et al have shown that Oncotype DX recurrence scores can be estimated by incorporating standard histologic variables into equations (Magee equations). Using a simple modification of the Magee equation, we predict the Oncotype DX recurrence score in an independent set of 283 cases. The Pearson correlation coefficient (r) for the Oncotype DX and average modified Magee recurrence scores was 0.6644 (n = 283; Po 0.0001). 100% of cases with an average modified Magee recurrence score430 (n = 8) or an average modified Magee recurrence score o9 (with an available Ki-67, n = 5) would have been correctly predicted to have a high or low Oncotype DX recurrence score, respectively. 86% (38/44) of cases with an average modified Magee recurrence score ≤ 12, and 89% (34/38) of low grade tumors (NS o6) with an ER and PR ≥ 150, and a Ki-67 o 10%, would have been correctly predicted to have a low Oncotype DX recurrence score. Using an algorithmic approach to eliminate high and low risk cases, between 5% and 23% of cases would potentially not have been sent by our institution for Oncotype DX testing, creating a potential cost savings between $56,550.00 and $282,750.00. The modified Magee recurrence score along with histologic criteria may be a cost-effective alternative to the Oncotype DX in risk stratifying certain breast cancer patients. The information needed is already generated by many pathology laboratories during the initial assessment of primary breast cancer, and the equations are free. Breast cancer is the most common non-cutaneous cancer in women, and the second most frequent cause of cancer death among women. 1 Approximately 50% of breast cancer cases are estrogen receptor (ER)-positive. 2 A major challenge in the treatment planning for breast cancer is to identify those patients who are more likely to develop recurrence, so that the most appropriate therapeutic regimen can be provided. The decisions around systemic therapy in breast cancer have traditionally been based on combinations of clinical and histopathologic risk factors including measures of proliferation, 3 tumor size, 4 histologic grade, 5 as well as lymph node staging. 6 In addition, breast cancer biomarkers including ER, progesterone receptor (PR), and the human epidermal growth factor receptor-2 (HER-2), are routinely assessed to provide further prognostic information as well as to help identify subsets of patients who are appropriate for specific targeted therapies. 7-9 These prognostic markers are very useful for identifying the higher risk triple negative or HER-2-positive cases; however, it remains challenging to accurately assess individual risk and the need for systemic chemotherapy for the lower risk subset of hormone receptor-positive patients on a case by case basis.
Breast cancer is the most common non-cutaneous cancer in women, and the second most frequent cause of cancer death among women. 1 Approximately 50% of breast cancer cases are estrogen receptor (ER)-positive. 2 A major challenge in the treatment planning for breast cancer is to identify those patients who are more likely to develop recurrence, so that the most appropriate therapeutic regimen can be provided. The decisions around systemic therapy in breast cancer have traditionally been based on combinations of clinical and histopathologic risk factors including measures of proliferation, 3 tumor size, 4 histologic grade, 5 as well as lymph node staging. 6 In addition, breast cancer biomarkers including ER, progesterone receptor (PR), and the human epidermal growth factor receptor-2 (HER-2), are routinely assessed to provide further prognostic information as well as to help identify subsets of patients who are appropriate for specific targeted therapies. [7] [8] [9] These prognostic markers are very useful for identifying the higher risk triple negative or HER-2-positive cases; however, it remains challenging to accurately assess individual risk and the need for systemic chemotherapy for the lower risk subset of hormone receptor-positive patients on a case by case basis.
Over the last decade, molecular approaches, including multigene assays for predicting prognosis and treatment response, have entered into the clinical arena of breast cancer care. 10, 11 Oncotype DX (Genomic Health, Redwood City, CA, USA) is a 21-gene commercial quantitative reverse transcription-polymerase chain reaction-based assay that quantifies the expression of 16 cancer-related genes. The remaining five genes are used to check RNA integrity and normalize expression levels. 12 The Oncotype DX test has been shown to be prognostic 12 and to be predictive of chemotherapy benefit 13 in ER-positive lymph node-negative breast cancer patients. There is some evidence to suggest that the use of Oncotype DX testing can provide additional information in predicting recurrence in women with lymph node-positive breast cancer as well. 14 Oncotype DX uses quantitative reverse transcription-polymerase chain reaction and an algorithm to calculate a recurrence score, giving the highest weight to proliferation (which includes Ki-67), followed by HER-2, ER, and PR. The Oncotype DX recurrence score is reported as a number that is divided into either low (o 18), intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , or high (430) recurrence risk categories.
Several studies have suggested that standard histopathologic variables can provide information similar to that provided by the Oncotype DX recurrence score. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Four of the 16 genes (ER, PR, HER-2, and Ki-67) measured as parts of the Oncotype DX panel are routinely assessed at the protein level by immunohistochemistry 28 in the routine diagnostic evaluation of breast cancer. Four linear regression analysis equations (Magee equations) have been published 15, 16 using several histopathologic variables, and semiquantitative results from these four immunophenotypic markers (ER, PR, HER-2, and Ki-67). In these studies, 15, 16 it was shown that standard histopathological variables in combination with semiquantitative ER, PR, HER-2, and Ki-67 results can be used in the Magee equations to calculate a recurrence score which correlated well with the Oncotype DX recurrence score, and provided information similar to that found in the Oncotype DX recurrence score.
The Magee equations use a semiquantitative scoring for ER and PR (the H-score) not used by all pathologists. In the current study, we have used a modification of the Magee equations in an institutional cohort of breast cancer cases that were sent for Oncotype DX from the University of Rochester Medical Center, Rochester, NY, USA. Our goal was to investigate whether or not these modified Magee equations, along with specific histologic and immunohistochemical criteria, might represent a costeffective alternative method of identifying ERpositive breast cancer patients who might either safely benefit from, or safely avoid, systemic chemotherapy.
Materials and methods

Patients and Data Retrieval
A total of 299 cases with available Oncotype DX recurrence scores were identified from the pathology files at the University of Rochester Medical Center (2009) (2010) (2011) (2012) (2013) . Demographic information on age was extracted from the medical record. All tumor H&E slides and immunohistochemistry were reviewed by at least two board-certified breast pathologists, with manual interpretation of ER, PR, HER-2, and Ki-67 (FDA-approved test kits (DAKO) -ERα (clones ID5 and ER-2-123); PR (clone PgR1294) pharmDxTM; Rabbit anti-human HER-2 HercepTestTM; Monoclonal mouse anti-human Ki-67 antigen (clone MIB-1, code M7240)). Fluorescence in situ hybridization was performed (FDA-approved test kit (DAKO) -HER-2 IQFISH pharmDxTM) on all equivocal HER-2 immunohistochemistry results, and the fluorescence in situ hybridization results were used in lieu of the immunohistochemistry for these cases. The Nottingham score (NS) was calculated using the Nottingham modification of the Bloom-Richardson system. 5 Information on tumor size was extracted from the pathology report. Sixteen cases were excluded because of lack of complete information on either NS, ER, PR, HER-2, or tumor size. A total of 283 cases (241 of these with Ki-67 results) were subsequently evaluated (244 invasive ductal carcinomas and 39 invasive lobular carcinomas).
Study Design
Flanagan et al 15 published the original Magee equation (recurrence score = 13.424+5.420 (nuclear grade)+5.538 (mitotic count) − 0. 045 (ER H-score) − 0.030 (PR H-score)+9.486 (0 for HER-2 negative/ equivocal and 1 for positive)) as a model to predict the Oncotype DX recurrence score. In a subsequent paper, building on the original equation, Klein et al 16 published three additional Magee equations (#1, #2, and #3) using different combinations of standard histopathologic variables (NS, ER, PR, HER-2, Ki-67, and tumor size). Using these most recent equations, 16 we calculated a modified Magee recurrence score by modifying the H-score for ER and PR. The H-score used in the original Magee equations estimates the percentage (0-100) of cells that are positive for each particular level of intensity (grade 0-3), multiplies this percentage by that intensity, and then adds the total of the percentage multiplied by intensity for the three intensity grades. For example, a sample block consisting of 100 tumor cells with an intensity of grade 0 in 10 cells, grade 1 in 20 cells, grade 2 in 50 cells, and grade 3 in 20 cells would give an H-score of ((0 × 10)+(1 × 20)+(2 × 50)+(3 × 20)) = 180. We estimated the H-score by considering the average intensity of staining, which is essentially the H-score/100:
We used the predominant intensity grade as a surrogate for the average intensity of staining, and multiplied this number by the total percentage of Use of modified Magee cells which stained positive. In the example given above, the actual average intensity of staining would have been 1.8. The predominant stating pattern would have been estimated to be 2. Ninety out of 100 of the cells stained positive. The estimated H-score would be 2 × 90 = 180. We also used the average of the three modified Magee recurrence scores to generate an average modified Magee recurrence score. If the modified Magee recurrence scores #1 and #3 were not calculated owing to unavailability of Ki-67 results, the modified Magee recurrence score #2 (which does not require a Ki-67) was used as a surrogate for the average modified Magee recurrence score.
Statistical Analysis
Available clinical and pathologic data were summarized using percentages, descriptive statistics (mean, range, frequencies) and inferential statistics (t-test). The risk categories used by the Oncotype DX recurrence score (low (o 18), intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , or high (430)) were applied to the modified Magee recurrence score, and the modified Magee recurrence scores were compared with their paired Oncotype DX recurrence scores for correlation (Pearson correlation) and concordance. We compared the average modified Magee recurrence score, ER, PR, and Ki-67 values at several cutoff points to determine how they stratified into the high and low Oncotype DX recurrence score risk stratification groups. The various cutoff points were then examined to determine which types of cases had the greatest likelihood of stratifying into either a high or low Oncotype DX risk stratification group, with the lowest likelihood of discordance. On the basis of these cutoff points, an algorithm was then created for which cases to consider sending for Oncotype DX testing. All data analyses were performed using the statistical Analysis ToolPak (Microsoft Excel Office 2010 version 14.0.7015.100) except for the likelihood ratios, which were performed using JavaStat 2-way Contingency 
Results
A summary of clinicopathologic features in the patient population is detailed in Table 1 .
Correlation and Concordance between Modified
Magee Recurrence Score and Oncotype DX Recurrence Score
There was an overall 68% (n = 241), 68% (n = 283), 70% (n = 241), and 70% (n = 283) agreement between the modified Magee recurrence score (equations #1, #2, #3 and the average modified Magee recurrence score, respectively) and the Oncotype DX recurrence score. The correlation between recurrence score and NS, ER, PR, HER-2, Ki-67, and tumor size was similar in both the modified Magee recurrence scores and the Oncotype DX recurrence score (Table 1) , with a pattern of increasing recurrence score with increasing NS, HER-2, Ki-67, and tumor size, and a pattern of increasing recurrence score with decreasing ER and PR. The average recurrence score, NS, ER, PR, Ki-67, HER-2, and tumor size for modified Magee recurrence score equations #1, #2, and #3 were not statistically different from the average recurrence score, NS, ER, PR, Ki-67, Her-2, and tumor size for the average modified Magee recurrence score (P40.1). The Pearson correlation coefficient (r) for the average modified Magee recurrence score and Oncotype DX recurrence score was 0.6644 (n = 283; P o 0.0001) with an average coefficient of determination (r 2 ) of 0.4414 ( Figure 1 ). Following the criteria Table 6 ).
Cost Analysis
The estimated cost of sending our 283 cases out for Oncotype DX testing, based on the current list price of $4,350.00, would be $1,231,050.00. 100% of cases with an average modified Magee recurrence score430 (n = 8), and 100% of cases with an average modified Magee recurrence score o 9 and an available Ki-67 (n = 5), would have been correctly predicted to have a high (430) or low (o 18) Oncotype DX recurrence score, respectively. These 13 cases would represent a more conservative approach (100% concordance in our population) in eliminating high and low risk cases from Oncotype DX testing. 86% of cases with an average modified Magee recurrence score ≤ 12 (38/44) would have been correctly predicted to have a low Oncotype DX recurrence score. The six outlier cases have been previously discussed ( 
Discussion
Although the Oncotype DX test has gained widespread acceptance, cost has been an impediment to its adoption in many centers throughout the United States, and internationally. Clark et al, 17 Zbytek Figure 2 Algorithm for sending cases for Oncotype DX testing.
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Use of modified Magee et al, 18 Kraus et al, 19 Cuzick et al, 20 Joh et al 30 concluded that breast oncology specialists tended to overestimate the risk of tumor recurrence compared with the Oncotype DX recurrence score; however, their study methods reflect most other studies that examine the correlation of histopathologic variables with the Oncotype DX recurrence score, in that specific quantitative criteria were not used. This was in part addressed by Allison et al, 26 who have proposed an algorithm stratifying low grade and high grade cancers based on levels of PR expression and a Ki-67 ≤ 10% or410%, respectively. Our data support the Allison et al study, and we propose more specific criteria with which ER-positive patients might be more likely to have a low or high Oncotype DX recurrence score. The algorithm in Figure 2 offers a stepwise approach using the average modified Magee recurrence score, along with histologic and immunohistochemical criteria, to consider cases which might possibly be excluded from Oncotype DX testing.
Several limitations in our study exist. The study set consisted of relatively recent archival cases, and there has not been sufficient time for clinical followup. Also, these cases were selected for Oncotype DX testing based on the clinical judgment of the medical oncologist, who would likely be biased toward patients with an indeterminate clinical risk assessment. Supporting this view is the low number of cases with a high recurrence score, which likely reflects the fact that patients who were judged to be at high recurrence risk based on standard histopathologic and clinical criterion were recommended for treatment with chemotherapy, and an Oncotype DX was not requested. As such, our study population might not be considered representative of the general breast cancer population. Nevertheless, our study is in agreement with Klein et al, 16 in that the use of the Magee equations can help to accurately stratify breast cancer patients into subgroups where the calculated recurrence score would be likely concordant with its paired Oncotype DX recurrence score. Study of the prognostic significance of the calculated recurrence score in the general breast cancer population, with clinical follow-up, is needed and is currently ongoing in our institution.
A second limitation is that we had a number of cases that did not have an available Ki-67 (n = 42), and we used the modified Magee recurrence score #2 (which does not require a Ki-67) as a surrogate for the average modified Magee recurrence score in these cases. Knowledge of the Ki-67 may have decreased the specificity of an algorithm which considered the average modified Magee recurrence score alone. Assuming theoretical Ki-67 values of ≥ 90% (an unlikely scenario) in the 42 cases without an available Ki-67, five cases with a modified Magee recurrence score #2 o 30, would have had an actual (not surrogate) average modified Magee recurrence score430. Only one of these five cases had an Oncotype DX recurrence score that was 430. The other four cases might have been recommended for exclusion from Oncotype DX testing (and possibly considered for treatment), based on the average modified Magee recurrence score alone. For cases with an available Ki-67, there was one case with a modified Magee recurrence score #2430 and an Oncotype DX recurrence score o 30. This case might have been recommended for exclusion from Oncotype DX testing (and possibly considered for treatment), based on the average modified Magee recurrence score alone, if there had been no Ki-67 available (i.e., using a surrogate average modified Magee recurrence score). There were 4/42 cases without an available Ki-67 that had a modified Magee recurrence score #2 o 9. Three of these cases had an Oncotype DX recurrence score of o 18, and would have supported an algorithm considering the average modified Magee recurrence score alone, given any Ki-67 value; however, assuming a theoretical Ki-67 value of ≤ 8%, the fourth case, which had an intermediate Oncotype DX recurrence score of 20, might have been recommended for exclusion from Oncotype DX testing (and possibly not considered for treatment), based on the average modified Magee recurrence score alone. For cases with an available Ki-67, there was one case with a modified Magee recurrence score #2 o 9 and an intermediate Oncotype DX recurrence score (19) , which might have been recommended for exclusion from Oncotype DX testing (and possibly not considered for treatment), based on the average modified Magee recurrence score alone, if there had been no Ki-67 available (i.e., using a surrogate average modified Magee recurrence score).
All of our cases with an available Ki-67 that had an average modified Magee recurrence score o 9 (n = 5) also had a modified Magee recurrence score #1 o 9, a modified Magee recurrence score #2 o 7.0, and a Ki-67 valueo 10%. Of note, no case had a modified Magee recurrence score #3 o9. All of our cases that had an average modified Magee recurrence score 430 (n = 8), also had at least two other modified Magee recurrence scores 430, and/or a modified Magee recurrence score #2 that was 430. We recommend that in addition to the average modified Magee recurrence score, the Ki-67 be should be available, and at least two other modified Magee recurrence scores should be considered, with one being a modified Magee recurrence score #2, when considering excluding cases from Oncotype DX testing (Figure 2) .
Another potential concern is the lack of reproducibility and reliability in the use of immunohistochemistry for applications. Differences in immunohistochemistry values may occur as a result of variability in a variety of factors including tissue handling, 31, 32 tissue fixation, reagents protocols, staining protocols, and pathologist interpretation. 32 In light of these concerns, several quality assurance programs have been created including ad hoc consensus conference recommendations, 33, 34 and the guideline recommendations from the American Society of Clinical Oncology/College of American Pathologist for HER-2, ER, and PR testing, 35, 36 which includes mandatory proficiency testing. These national efforts have led to marked improvements in the quality, reliability, and inter-laboratory agreement for these breast cancer assays, [37] [38] [39] [40] [41] and have made the use of semiquantitative immunohistochemistry results more feasible for estimating risk. These efforts in improving quality may be most helpful in reconsidering the role of Ki-67 as part of the routine panel for testing of breast cancers. Routine testing of breast cancers for Ki-67 expression is not currently recommended by either the American Society of Clinical Oncology or the National Comprehensive Cancer Network. 42, 43 Our data support other studies [22] [23] [24] 26, 27 which suggest that Ki-67 is critical in the assessment of risk stratification for patients with ER-positive breast cancer patients who are being considered for systemic chemotherapy.
The cost of the Oncotype DX test has been quoted anywhere from $3,460.00 to $4,400.00, with the current list price recently increased from $4,175.00 to $4,350.00. 44 Consideration of a cost-effective approach in deciding which patients should be sent for Oncotype DX testing cannot be overlooked in this era of cost-conscious health care. In the Genomic Health 2012 Annual Report, 44 the Letter to Stockholders reported a '12% increase compared to 2011', with 'total revenue increased by 14%, rising to $235,000,000 compared with the previous year.' In that same report, 'for the year ended December 31, 2012, more than 74,520 Oncotype DX test reports were delivered for use for treatment planning,' and approximately 85% of revenue from Oncotype DX testing was reported to come from invasive breast carcinoma testing. If we considered that approximately 85% of the 74,520 reported 2012 Oncotype DX test reports were invasive breast cancer cases, then 63,342 Oncotype DX test reports were generated for invasive breast cancer cases. The Oncotype DX risk stratification of these cases is unknown; however, we might envision a reasonable costcontainment scenario. Depending on the pathologist in the Paik et al 12 study, between 107 (16%) and 224 (34%) of cases were considered 'low grade' tumors. In our study, we had 141 (50%) low grade tumors. Considering only low grade tumors, 6/141 (5%) in our population had an average modified Magee recurrence score o 9 which would have satisfied our algorithmic criteria for exclusion from Oncotype DX testing. If we considered the most conservative scenario in which approximately 16% (based on the Paik et al 12 study) of the suspected 63,342 invasive breast tumors sent to Genomic Health for Oncotype DX testing in 2012 were low grade (n = 10,135), and that 5% (based on our data) of these tumors (n = 460) had an average modified Magee recurrence score o 9 which satisfied the algorithmic criteria, the estimated cost savings to the health-care system from not sending these tumors for Oncotype DX testing (based on the current list price) would be approximately $2,001,000.00. If we also were able to exclude subsets of cases satisfying our algorithmic criteria that either had an average modified Magee recurrence score 430, an average modified Magee recurrence score ≤ 12, and/or a NS o 6 with an ER/ PR ≥ 150 and a Ki-67 o 10%, the cost savings would undoubtedly be substantially higher.
Analysis of the data from the B20 clinical trial 13 and Oncotype DX results suggested that the benefit from the addition of chemotherapy was only significant for the group of patients with a recurrence score of 425, whereas the confidence intervals for the risk of relapse showed complete overlap in the 11-25 recurrence score range. 45 In the Trial Assigning Individualized Option for Treatment (TAILORx), the recurrence score ranges used for enrollment were changed from the original definitions, such that patients with a recurrence score of 425 were to receive chemotherapy, and those in the 11-25 range would be randomized, in an attempt to minimize the potential for under treatment in both the high risk group and the randomized group. 45 The results of this study have not been published yet. In our population, 100% of tumors with an average modified Magee recurrence score ≤ 12 (n = 44) or a NS o 6 with an ER of ≥ 150, PR ≥ 60, and Ki-67 o 20% (n = 75) had an Oncotype DX recurrence score of ≤ 25. 98% (113/115) of all cases with an ER of ≥ 150, PR ≥ 150, and Ki-67 o 25% had an Oncotype DX recurrence score of ≤ 25. 99% (134/136) of all cases with an ER and PR ≥ 30, and a Ki-67 o 20% had an Oncotype DX recurrence score ≤ 25. The two outlier cases were the same in both groups, with Oncotype DX recurrence scores of 26 and 28, and an average modified Magee recurrence score, NS, ER, PR, Ki-67, Her-2, and tumor size of 14.6, 7, 285, 240, 5, 0, and 1.5 and 12.5, 6, 285, 270, 5, 1, and 1.5, respectively. We look forward to the results of the TAILORx study.
Examination of the available data provided in the Paik et al 12 study shows that there were several patients in the low to intermediate histologic grade category with higher Oncotype DX recurrence scores, similar to our two outlier cases above. Although it is reasonable to consider that higher Oncotype DX recurrence scores in the patients with low to intermediate histologic grade tumors in the Paik et al study were at least in part due to lower ER and/or PR values, or a mitotically active tumor, the possibility that the tumor microenvironment contributed to a higher Oncotype DX recurrence score should also be considered. Acs et al and others 26, 46 have suggested that a mitotically active cellular stroma, or tumor-associated inflammatory cells, may contribute to a higher Oncotype DX recurrence score. We are currently investigating this concept of the tumor microenvironment and its influence on the Oncotype DX recurrence score in our own data, and we plan to report our results in a future publication.
Oncotype DX testing is supported by both the American Society of Clinical Oncology and the National Comprehensive Cancer Network for guiding management in breast cancer patients with nodenegative, ER-positive disease, 42, 43 and is clearly recognized as a valuable test in the literature. 30, [47] [48] [49] However, the widespread use of this test has come into question recently, as the literature has suggested that certain cases might be risk stratified more costeffectively using histopathologic variables. [50] [51] [52] [53] [54] Our data support this. The Magee equations, along with histologic and immunohistochemical criteria, may be a more cost-effective alternative in identifying cases that would likely stratify into a high or low Oncotype DX risk-stratification category. The information needed is already generated by many pathology laboratories during the initial assessment of primary breast cancer. The equations are userfriendly and publicly available free of any cost. All three equations can be accessed on the University of Pittsburgh Medical Center Department of Pathology website: (http://path.upmc.edu/onlineTools/mageeE quations.html). The modified Magee equations provide an alternative to the original Magee equations for pathology laboratories that do not use the H-score to determine ER and PR intensity.
It is important to emphasize that the use of these equations is heavily dependent on accurate histology grading and high quality ER, PR, HER-2, and Ki-67 immunohistochemical results. In cases where Oncotype DX testing is done, the Magee recurrence score should not be dramatically different from the Oncotype DX recurrence score. If there is a significant difference, this should be thoroughly investigated before decisions on adjuvant therapy are made. Additional studies to further validate the suggested algorithm are needed.
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